Oosterhuis Ingrid, Rolfes Leàn, Ekhart Corine, Muller-Hansma Annemarie, Härmark Linda
a Netherlands Pharmacovigilance Centre Lareb , 's-Hertogenbosch , The Netherlands.
b Unit of PharmacoTherapy, - Epidemiology & -Economics , Groningen Research Institute of Pharmacy, University of Groningen , Groningen , The Netherlands.
Expert Opin Drug Saf. 2018 Feb;17(2):111-115. doi: 10.1080/14740338.2018.1400008. Epub 2017 Nov 20.
BACKGROUND: To make a proper causality assessment of an adverse drug reaction (ADR) report, a certain level of clinical information is necessary. A tool was developed to measure the level of clinical information present in ADR reports. The aim of this study was to test the validity and reliability of the clinical documentation tool (ClinDoc) in an international setting. METHODS: The tool was developed by a panel of pharmacovigilance experts. It includes four domains: ADR, chronology of the ADR, suspected drug and patient characteristics. The final score categorizes reports into: excellent, well, moderately or poorly documented. In two rounds, eight pharmacovigilance assessors of different countries made a total of 224 assessments using the tool, with the expert panels judgement as a standard. Sensitivity and specificity were calculated. RESULTS: The tool with four outcome-categories demonstrated low sensitivity. A lack of distinctiveness was demonstrated between the categories moderate and well. Results for the second round were re-analysed using three categories. This demonstrated a better validity. CONCLUSION: This is the first tool to give insight in the level of relevant clinical information present in ADR reports. It can be used internationally to compare reports coming from different reporting methods and different types of reporters in pharmacovigilance.
背景:为了对药品不良反应(ADR)报告进行恰当的因果关系评估,一定水平的临床信息是必要的。开发了一种工具来衡量ADR报告中临床信息的水平。本研究的目的是在国际环境中测试临床文档工具(ClinDoc)的有效性和可靠性。 方法:该工具由一组药物警戒专家开发。它包括四个领域:ADR、ADR的时间顺序、可疑药物和患者特征。最终得分将报告分为:记录优秀、良好、中等或较差。在两轮中,来自不同国家的八位药物警戒评估人员使用该工具进行了总共224次评估,并以专家小组的判断为标准。计算了敏感性和特异性。 结果:具有四个结果类别的工具显示出较低的敏感性。中等和良好类别之间缺乏明显差异。第二轮结果使用三个类别重新进行了分析。这显示出更好的有效性。 结论:这是第一个能够洞察ADR报告中相关临床信息水平的工具。它可在国际上用于比较药物警戒中来自不同报告方法和不同类型报告者的报告。
Pharmacoepidemiol Drug Saf. 2018-8-30
Naunyn Schmiedebergs Arch Pharmacol. 2017-10-23
Sante Publique. 2019
Expert Opin Drug Saf. 2018-12-21
J Clin Pharmacol. 2021-2
Pharmacoepidemiol Drug Saf. 2025-7
Br J Clin Pharmacol. 2021-12